APA (7th ed.) Citation

MG, F., AP, J., L, W., LH, H., P, M., E, H., . . . AP, M. (2024). Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: Clinical implications as a potential therapeutic target. Oncogene, 43(7), 484. https://doi.org/10.1038/s41388-023-02925-x

Chicago Style (17th ed.) Citation

MG, Ferrari, et al. "Myeloid Differentiation Factor-2/LY96, a Potential Predictive Biomarker of Metastasis and Poor Outcomes in Prostate Cancer: Clinical Implications as a Potential Therapeutic Target." Oncogene 43, no. 7 (2024): 484. https://doi.org/10.1038/s41388-023-02925-x.

MLA (9th ed.) Citation

MG, Ferrari, et al. "Myeloid Differentiation Factor-2/LY96, a Potential Predictive Biomarker of Metastasis and Poor Outcomes in Prostate Cancer: Clinical Implications as a Potential Therapeutic Target." Oncogene, vol. 43, no. 7, 2024, p. 484, https://doi.org/10.1038/s41388-023-02925-x.